Oncomed Pharmaceuticals (NASDAQ:OMED) posted its quarterly earnings results on Thursday. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.34, AR Network reports.
Oncomed Pharmaceuticals (NASDAQ:OMED) traded down 2.78% on Friday, hitting $22.00. 25,112 shares of the company’s stock traded hands. Oncomed Pharmaceuticals has a 52-week low of $12.07 and a 52-week high of $42.34. The stock’s 50-day moving average is $27.95 and its 200-day moving average is $27.06. The company’s market cap is $648.6 million.
Several analysts have recently commented on the stock. Analysts at Jefferies Group cut their price target on shares of Oncomed Pharmaceuticals from $50.00 to $48.00 in a research note on Friday. On a related note, analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, March 25th. They now have a $31.60 price target on the stock. Finally, analysts at Mizuho initiated coverage on shares of Oncomed Pharmaceuticals in a research note on Monday, February 10th. They set a “buy” rating and a $45.00 price target on the stock. One research analyst has rated the stock with a sell rating and three have given a buy rating to the stock. Oncomed Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $40.92.
OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.